Year Published
- 2008 (0)
- (-) Remove 2009 filter 2009
- 2010 (0)
- 2011 (0)
- 2012 (1) Apply 2012 filter
- 2013 (0)
- 2014 (0)
- 2015 (1) Apply 2015 filter
- 2016 (3) Apply 2016 filter
- (-) Remove 2017 filter 2017
- (-) Remove 2018 filter 2018
- 2019 (1) Apply 2019 filter
- 2020 (0)
- 2021 (0)
Research Topics
Populations
Types of Research
- Data Analysis (3) Apply Data Analysis filter
- Literature Review (3) Apply Literature Review filter
- Portfolio Review (0)
- Research Brief (0)
Geography
- (-) Remove East Africa Region and Selected Countries filter East Africa Region and Selected Countries
- (-) Remove Global filter Global
- South Asia Region and Selected Countries (2) Apply South Asia Region and Selected Countries filter
- (-) Remove Southern Africa Region and Selected Countries filter Southern Africa Region and Selected Countries
- Sub-Saharan Africa (9) Apply Sub-Saharan Africa filter
- West Africa Region and Selected Countries (2) Apply West Africa Region and Selected Countries filter
Dataset
Current search
- (-) Remove East Africa Region and Selected Countries filter East Africa Region and Selected Countries
- (-) Remove 2017 filter 2017
- (-) Remove Southern Africa Region and Selected Countries filter Southern Africa Region and Selected Countries
- (-) Remove Global filter Global
- (-) Remove 2018 filter 2018
- (-) Remove 2009 filter 2009
- (-) Remove Technology filter Technology
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
In this report we analyze three waves nationally-representative household survey data from Kenya, Uganda, Tanzania, Nigeria, Pakistan, Bangladesh, India, and Indonesia to explore sociodemographic and economic factors associated with mobile money adoption, awareness, and use across countries and over time. Our findings indicate that to realize the potential of digital financial services to reach currently unbanked populations and increase financial inclusion, particular attention needs to be paid to barriers faced by women in accessing mobile money. While policies and interventions to promote education, employment, phone ownership, and having a bank account may broadly help to increase mobile money adoption and use, potentially bringing in currently unbanked populations, specific policies targeting women may be needed to close current gender gaps.
An ongoing stream of EPAR research considers how public good characteristics of different types of research and development (R&D) and the motivations of different providers of R&D funding affect the relative advantages of alternative funding sources. For this project, we seek to summarize the key public good characteristics of R&D investment for agriculture in general and for different subsets of crops, and hypothesize how these characteristics might be expected to affect public, private, or philanthropic funders’ investment decisions.
Land tenure refers to a set of land rights and land governance institutions which can be informal (customary, traditional) or formal (legally recognized), that define relationships between people and land and natural resources (FAO, 2002). These land relationships may include, but are not limited to, rights to use land for cultivation and production, rights to control how land should be used including for cultivation, resource extraction, conservation, or construction, and rights to transfer – through sale, gift, or inheritance – those land use and control rights (FAO, 2002). In this project, we review 38 land tenure technologies currently being applied to support land tenure security across the globe, and calculate summary statistics for indicators of land tenure in Tanzania and Ethiopia.
A “new wave” of digital credit products has entered the digital financial services (DFS) market in recent years. These products differ from traditional credit by offering loans to borrowers that can be applied for, approved, and disbursed remotely (often without any brick-and-mortar infrastructure), automatically (generally minimizing or eliminating person-to-person interaction), and instantly (often in less than 72 hours). Digital credit also increasingly considers creditworthiness by using alternative (nontraditional) data—ranging from mobile phone activity to utility payments and social media data—potentially allowing for loans to populations previously unable to access bank credit. Two EPAR reports review the characteristics of digital credit offerings in India, Kenya, Nigeria, Tanzania, and Uganda, and regulations specific to digital credit in Africa and Asia.